A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy
- EligibilityCriteria: Inclusion Criteria:  Sign informed consent and join the study voluntarily; Patients diagnosed with extensive small cell lung cancer; Age ≥18 years old; Have at least one measurable lesion (according to RECIST 1.1); The investigators judged that adebrelimab treatment was acceptable; Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;  Exclusion Criteria:  Allergic to adebrelimab and its excipients; Patients who have also received other immune drugs or therapies; Patients who are participating in other interventional studies; patients with other malignant tumors; Pregnant or lactating women; The investigator considers that the patient is not suitable to participate in any other conditions of the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with extensive stage small cell lung cancer treated with adebrelimab - SamplingMethod: Non-Probability Sample